Certara, Inc. (CERT)
| Market Cap | 2.34B |
| Revenue (ttm) | 352.96M |
| Net Income (ttm) | -33.73M |
| Shares Out | 159.85M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | 30.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 547,738 |
| Open | 14.35 |
| Previous Close | 14.41 |
| Day's Range | 14.12 - 14.67 |
| 52-Week Range | 11.81 - 24.96 |
| Beta | 1.51 |
| Analysts | Buy |
| Price Target | 50.29 (+243.51%) |
| Earnings Date | Nov 8, 2023 |
About CERT
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled se... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is $50.29, which is an increase of 243.51% from the latest price.
News
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Certara Reports Third Quarter 2023 Financial Results
PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023.
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 a...
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines
Certara to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor co...
Certara Simcyp™ Group Awarded Two New Grants from US FDA
Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of ...
Certara stock drops after biotech software company misses profit target
Certara Inc. CERT, -2.56% stock was down 14.6% in premarket trades on Thursday after the biotech software company missed Wall Street's adjusted earnings and revenue targets and said its 2023 profit wo...
Certara Reports Second Quarter 2023 Financial Results
PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023.
Certara & Xybion Partner to Integrate Nonclinical R&D Software to Streamline Assessing Drug Safety & Efficacy
PRINCETON, NJ / ACCESSWIRE / August 8, 2023 / Xybion Digital Inc. (TSXV:XYBN) ("Xybion"), a global, low-code SaaS company that enables digital transformation in highly regulated labs and Certara, Inc....
Certara collaborates with Korea Institute of Toxicology to ensure FDA submission-ready SEND dataset
SEOUL, South Korea--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in Biosimulation, today announced that a Korea Institute of Toxicology (KIT) have decided to implement Certara's Pinn...
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023...
Certara to Participate in the Jefferies Global Healthcare Conference
PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Heal...
Certara Reports First Quarter 2023 Financial Results
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023.
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
Asserts Certara's leadership in advancing the development and approval of new drugs for patients Asserts Certara's leadership in advancing the development and approval of new drugs for patients
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023...
Are These 3 Small Momentum Stocks Setting Up Big Gains?
MINISO Group Holding Limited (NYSE: MNSO), PDF Solutions Inc. (NASDAQ: PDFS), and Certara Inc. (NASDAQ: CERT) are relatively unknown stocks currently showing strong price momentum.
A.I. Coming to Certara's D360 Scientific Informatics Software
New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses. New deep learning capabilities will provide data a...
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies Simcyp Simulator has been utilized to inform more than 300 label clai...
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency Annual Revenue Grows 17% on a Reported Basis and 20% at Constant Currency
Certara Announces Transition Plan for Chief Financial Officer
PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1, 2023. ...
Certara to Participate in the Barclays Global Healthcare Conference
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healt...
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and ful...
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Certara improves software capabilities by expanding into deep learning and data fabric Certara improves software capabilities by expanding into deep learning and data fabric
Certara Announces the Completion of Arsenal Capital Partners' Investment and the Appointment of David Spaight to the Board of Directors
Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Private Equity Arsenal closed the previously announced $449M stock purchase from funds controlled by EQT Priva...
Certara Reports Third Quarter 2022 Financial Results
Biosimulation software and services fuel third quarter growth Biosimulation software and services fuel third quarter growth